Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Alivio Therapeutics.

    Client Virtual Booth

    ALIVIO THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Alivio Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    501 Boylston Street | Suite 6102 | Boston, MA 02116
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.aliviotherapeutics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter
    https://twitter.com/hashtag/aliviotherapeutics

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics

    Details:

    The Wholly Owned Pipeline will include the addition of LYT-500. LYT-500 contains a unique combination of IL-22 and an anti-inflammatory drug, which is designed to address the two key underlying causes of IBD pathogenesis and progression.


    Lead Product(s): IL-22,Anti-inflammatory drug

    Therapeutic Area: Gastroenterology Product Name: LYT-500

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: PureTech Health

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition June 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense

    Details:

    The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.


    Lead Product(s): ALV-304

    Therapeutic Area: Gastroenterology Product Name: ALV-304

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: U.S. Department of Defense

    Deal Size: $3.3 million Upfront Cash: Undisclosed

    Deal Type: Funding October 05, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search